基石藥業(2616.HK)拉昇漲近10% 有望創年內新高價
格隆匯5月21日丨延續近日凌厲漲勢,基石藥業(2616.HK)今日盤中繼續拉昇,一度漲近10%報11.9港元,股價逼近2月份高位,有望創出年內新高價,最新市值140億港元。公司12日公佈,avapritinib新藥上市申請在香港地區獲受理,avapritinib是一款強效、高選擇性口服KIT和PDGFRA抑制劑,用於治療PDGFRAD842V突變無法切除或轉移性胃腸道間質瘤成人患者,此前已在全國多地開出首批處方單。另外,公司此前還宣佈精準治療產品艾伏尼布(ivosidenib)獲美國FDA優先審評用於治療膽管癌。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.